Immunological and Autoimmune Disorders

PureHealth acquires LYT-100 to treat lymphedema PureTech Health, a pioneer in the development of therapies for dysfunctions in the brain-immune-gut axis, has announced to acquire a clinical-stage drug, LYT-100 for the potential treatment of lymphatic and immunofibrotic diseases including lymphedema. The candidate, LYT-100, is an oral, small molecule, has been acquired from a pharma company where it was under clinical trials for other indication. The candidate exhibited anti-fibrotic and anti-inflammatory mechanisms and was well tolerated in preclinical studies, with a favourable pharmacokinetic profile to support twice-daily oral dosing. With the acquisition of the...